Skadden advised ClouDr Group Limited on its initial public offering and listing on the Main Board of the Hong Kong Stock Exchange. ClouDr offered 19,000,000 shares at HK$30.50 per share, raising a total value of HK$579.5 million (approximately US$73.8 million), exclusive of over-allotment options. Trading commenced on July 6, 2022.
ClouDr is the largest digital chronic condition management solution provider in China based on the number of SaaS installations in hospitals and pharmacies as well as number of online prescriptions issued.
The Skadden team was led by partners Haiping Li (Shanghai), Paloma Wang (Hong Kong) and Kai Sun (Hong Kong/Beijing), with Asia Pacific counsel Weiwei Chen (Hong Kong), associates Charles Shi (Hong Kong), Weijian You (Shanghai), Julia Liu (Hong Kong) and Robin Sun (Shanghai), international project manager Evelyn Ou (Shanghai) and staff attorney Jessica Chan (Hong Kong).
